TriSalus Life Sciences Stock

trisaluslifesci.comHealthcare / BioTech & PharmaFounded: 2009Funding to Date: $198.81MM

TriSalus Life Sciences is a biopharma company that specializes in treatment research and development for tumors of the liver and pancreas. TriSalus involves a team of clinicians and scientists who develop systemic immunotherapies to fight tumors through its developed drug delivery methods.

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to TriSalus Life Sciences before its SPAC, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

TriSalus Life Sciences Stock Price

Forge Price 1
Price not available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

TriSalus Life Sciences Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
10/05/2022 Series B-2 $15.32MM $xx.xx $375.88MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
43,775,511
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
09/29/2021 Series B-3 $17.14MM $xx.xx $356.56MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
342,857,136
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
09/29/2021 Series B-1 $23.5MM $xx.xx $356.56MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
67,142,854
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
03/18/2021 Series B $85.22MM $xx.xx $161.99MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
284,065,377
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
03/02/2017 Series A-6 $16.3MM $xx.xx $80.61MM Ori Healthcare Fund
Price per Share
$xx.xx
Shares Outstanding
32,601,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ori Healthcare Fund
12/02/2015 Series A-4 $2.05MM $xx.xx $55.51MM High Country Venture, Kmg Capital Partners, Mcg Partners, Partisan Management Group, Tullis Health Investors
Price per Share
$xx.xx
Shares Outstanding
5,169,690
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
High Country Venture, Kmg Capital Partners, Mcg Partners, Partisan Management Group, Tullis Health Investors
12/02/2015 Series A-5 $13.08MM $xx.xx $55.51MM High Country Venture, Kmg Capital Partners, Mcg Partners, Partisan Management Group, Tullis Health Investors
Price per Share
$xx.xx
Shares Outstanding
29,715,910
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
High Country Venture, Kmg Capital Partners, Mcg Partners, Partisan Management Group, Tullis Health Investors
11/07/2013 Series A-2 $9.02MM $xx.xx $45.95MM Mcg Partners, Partisan Management Group & High Country Ventures
Price per Share
$xx.xx
Shares Outstanding
23,307,464
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Mcg Partners, Partisan Management Group & High Country Ventures
11/07/2013 Series A-3 $10.66MM $xx.xx $45.95MM Mcg Partners, Partisan Management Group & High Country Ventures
Price per Share
$xx.xx
Shares Outstanding
24,792,020
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Mcg Partners, Partisan Management Group & High Country Ventures
07/06/2011 Series A-1 $6.53MM $xx.xx $18.65MM High Country Venture, Partisan Management Group
Price per Share
$xx.xx
Shares Outstanding
5,331,943
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
High Country Venture, Partisan Management Group

Leadership & Board

Leadership

Mary Szela
Chief Executive Officer and President
Steven C. Katz, MD, FACS
Chief Medical Officer, Scientific Advisory Board Chairman
Sean Murphy
Chief Financial Officer
Trevor McCaw
Chief Commercial Officer
Bryan F. Cox, PhD
Chief of Research
Jennifer L. Stevens, JD
Chief Regulatory Officer
Richard B. Marshak VMD, MBA
Business Development & Strategy, SVP

Board

Beverly Huss
Vibrynt
Sean Murphy
Malin Corporation
John Tullis
Tullis Health Partners
Norman Weldon
Partison Management Group
Karen Cassidy
Partisan Management Group
Mark T. Lupa
High Country Venture
Ginger Graham
Independent Director
Mats Wahlstrom
KMG Capital Partners

TriSalus Life Sciences stock FAQs

plusminus

Can you buy TriSalus Life Sciences stock?

You can no longer buy TriSalus Life Sciences stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

How to buy TriSalus Life Sciences stock?

You can no longer buy TriSalus Life Sciences stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell TriSalus Life Sciences stock?

You can no longer sell stock of TriSalus Life Sciences on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

How to sell TriSalus Life Sciences stock?

You can no longer sell stock of TriSalus Life Sciences on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

Is TriSalus Life Sciences a public company?

TriSalus Life Sciences is now a public company traded on NASDAQ with ticker TLSI.
plusminus

What is TriSalus Life Sciences’ stock price?

The stock price of TriSalus Life Sciences is $8.3 as of 1/18/24.
plusminus

What is TriSalus Life Sciences’ stock ticker symbol?

The ticker symbol of TriSalus Life Sciences is TLSI.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

TriSalus Life Sciences News and Media Highlights

TriSalus merges with MedTech Acquisition to bolster cash reserves

TriSalus Life Sciences has merged with MedTech Acquisition Corporation to increase their cash reserves and fund developmental and commercial milestones. The merged company will trade on Nasdaq under the symbols "TLSI" and "TLSIW". The merger is expected to provide a cash runway until mid-2024 to support various plans, including the development of a cancer therapy.
Browse Insights
Updated on: Dec 1, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.